Cyclo Therapeutics: Addressing The Fundamentals Of Alzheimer's Disease

Nov. 16, 2021 1:47 AM ETCyclo Therapeutics, Inc. (CYTH)48 Comments
Lane Simonian profile picture
Lane Simonian
2.28K Followers

Summary

  • By reducing cholesterol levels, Trappsol Cyclo may impede the onset and early progression of Alzheimer's disease.
  • By scavenging peroxynitrite, Trappsol Cyclo can potentially reverse part of the damage that occurs to the brain during Alzheimer's disease.
  • Cyclo Therapeutics has a high upside and at this point presents very few risks to investors.

USA, Washington, Mt. Rainier National Park, wildflowers and hiker

Rene Frederick/DigitalVision via Getty Images

Cyclo Therapeutics' (NASDAQ:CYTH) launch into the Alzheimer’s field began with one case study that produced the following results:

After 18 months, the patient showed neurologic and cognitive stability: this is a positive outcome given that persons

This article was written by

Lane Simonian profile picture
2.28K Followers
Retired history instructor. Alzheimer's disease researcher for the past decade.My goal is to give investors solid advice based on the mechanisms of action of Alzheimer's drugs.  This advice is informed by  a background in biology (conservation, ecology, evolution, environmental science, and biochemistry) and seventeen years of a very in depth review of the research on Alzheimer's disease.

Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (48)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.